Hopital Des Enfants — Clinical Trial Site

45 Registered trials

22 Currently recruiting

Organisation

Hopital Des Enfants

Location

Toulouse Cedex 9, France

Identifier

ORG-100026949

Address

330 Avenue De Grande Bretagne, 31059, France

Departments

-
#2102:Equipe de gastroentérologie, hépatologie, nutrition et maladies héréditaires du métabolisme
#2307: Pneumologie Pédiatrique et Allergologie
1904: Neurologie pédiatrique
2304: Pédiatrie
Cardiologie pédiatrique
CHU Toulouse - Hôpital des Enfants
CHU Toulouse, Endocrinology Unit, Obesity, Bone Diseases, genetics and Medical Gynecology
endocrinologie, gynécologie et génétique médicale
Endocrinology, Gynecology & Medical Genetics
Gastro-entérologie, hépatologie, nutrition et maladies héréditaires du métabolisme
Gastroenterology, Hepatology, Nutrition and Diseases Hereditary Metabolism
Hémato-Immmuno-Onco-Pediatry
Hopital des enfants Hematologie, oncologie
N/A
NA
Neurologie, Infectiologie Pédiatrique
Onco-pediatry
ONCOLOGIE
Oncology for pediatrics
Paediatric Oncology
PEDIATRIC ENDOCRINOLOGY
Pediatric Endocrinology Department
Pediatric Hematology, Immunology and Oncology
Pediatric Nephrology
Pediatric oncology
Pediatrics
Pédiatrie - Endocrinologie, génétique et gynécologie médicale
Pediatry
Pôle de Pédiatrie (Equipe Ressource Régionale de Soins Palliatifs Pédiatriques Midi-Pyrénées)
Recherche clinique Pédiatrique
Service d'Hémato-oncologie
Service de Gastroenterologie, Hepatologie, Nutrition et Maladies Hereditaires du Metabolisme
service de Neuropédiatrie
Service de Pédiatrie - Néphrologie, médecine interne et hypertension
Unité d’Endocrinologie, Maladies Osseuses et Génétique
Unité de Gastroentérologie, Hépatologie, Nutrition et Diabétologie pédiatriques
Unité de Neurologie
Urgences pédiatriques

Clinical trials at this site (45)

Search interface

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat… Pending

2022-502365-26-00 Asthma 5
SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity seco… Pending

2024-511114-20-00 Craniopharyngioma 5
SPARE : Stopping Pneumonia Antibiotherapy Regimen Early Pending

2024-512236-30-00 Community-acquired alveolar pneumonia in children 5
BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending

2024-516115-24-00 High risk relapsed neuroblastoma (relapsed or progresse 9
A Study of Vosoritide in Children with Noonan Syndrome with Inadequate Growth During or After Human Growth Hormone Treatment Recruiting

2024-515861-33-00 Noonan Syndrome 4 2025-03-25
A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d… Recruiting

2022-502289-25-00 Moderate to Severe Active Systemic Lupus Erythematosus 5 2024-08-28
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome Recruiting

2023-505140-19-00 Childhood Idiopathic Nephrotic Syndrome 5 2023-07-31
A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting

2023-509810-13-00 Acute Lymphoblastic Leukemia (ALL) 4 2023-05-13
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral oza… Recruiting

2023-509248-86-00 Moderately to Severely Active Ulcerative Colitis 10 2022-03-11
Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in … Recruiting

2024-516807-17-00 Relapsing/Refractory ALK+ Anaplastic Large cell Lymphom 4 2019-01-02
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting

2023-504694-20-00 pediatric CD22-positive relapsed/refractory Acute Lymph 9 2017-01-13
Long-Term Extension Study of Vosoritide to Treat Children with Hypochondroplasia Recruiting

2024-517238-16-00 Hypochondroplasia 5 2026-01-28
A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting

2024-514974-39-00 Developmental and Epileptic Encephalopathies (DEEs) 5 2025-10-10
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature Recruiting

2024-520137-74-00 Idiopathic Short Stature (ISS) 4 2025-10-10
Long Term Study of Livmarli Recruiting

2024-516804-40-00 Alagille syndrome 6 2025-09-25
A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Shiga toxin-producing Escherichia coli-ass… Recruiting

2024-512412-22-00 Hemolytic Uremic Syndrome 5 2025-06-24
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Recruiting

2024-514937-39-00 Dravet Syndrome 5 2025-05-20
A Phase 3 Efficacy and Safety Study of Pitolisant in Patients with Prader-Willi Syndrome Recruiting

2023-508307-21-00 Prader-Willi syndrome 5 2025-03-19
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Patients with High Risk Neuroblastoma 5 2024-11-21
Long-term safety and tolerability of inclisiran in participants with heterozygous familial hypercholesterolaemia or homozygous familial hype… Recruiting

2023-507278-41-00 Familial hypercholsterolemia 5 2023-02-10
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Ch… Recruiting

2024-512382-13-00 Migraine (with or without aura) 5 2022-10-04
Venetoclax in children with relapsed AML Recruiting

2023-510160-12-00 acute myeloid leukemia 5 2022-08-16
A study to evaluate long-term Infigratinib in children with Achondroplasia Recruiting

2024-513857-55-00 Achondroplasia 4 2022-02-08
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica… Recruiting

2022-501454-11-00 standard risk ALK-positive anaplastic large cell lympho 5 2020-02-05